← Back to Search

Tirofiban Hydrochloride for Ischemic Stroke (iTREMT Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by University of Iowa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 day post- discharge follow up
Awards & highlights

iTREMT Trial Summary

This study is evaluating whether a medication may help improve outcomes for individuals who have had a stroke.

Eligible Conditions
  • Ischemic Stroke
  • Stroke

iTREMT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 day post- discharge follow up
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 day post- discharge follow up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Infract Size
Intracranial Hemorrhage
Secondary outcome measures
Modified Rankin Score
NIH Stroke Scale

Side effects data

From 2015 Phase 4 trial • 140 Patients • NCT03114995
13%
Minor bleeding
100%
80%
60%
40%
20%
0%
Study treatment Arm
Group A (High Platelet Reactivity - Tirofiban)
Control C1 (High Platelet Reactivity - no Tirofiban)
Control C2 (Low Platelet Reactivity - no Tirofiban)

iTREMT Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment Arm (tirofiban hydrochloride (AGGRASTAT®))Experimental Treatment1 Intervention
Subjects will receive an active dose via continuous IV at a rate of 0.10µg/kg/min (actual weight). This rate will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.
Group II: Placebo ArmPlacebo Group1 Intervention
Subjects will receive placebo (saline) via continuous IV. This will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.

Find a Location

Who is running the clinical trial?

University of IowaLead Sponsor
446 Previous Clinical Trials
879,502 Total Patients Enrolled
2 Trials studying Ischemic Stroke
190 Patients Enrolled for Ischemic Stroke

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke
David Hasan 2023. "Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04818944.
~0 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top